as 10-28-2024 4:00pm EST
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Founded: | 2007 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 96.2M | IPO Year: | 2020 |
Target Price: | $6.00 | AVG Volume (30 days): | 2.0M |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.18 | EPS Growth: | N/A |
52 Week Low/High: | $1.14 - $4.02 | Next Earning Date: | 11-08-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BCAB Breaking Stock News: Dive into BCAB Ticker-Specific Updates for Smart Investing
Insider Monkey
9 days ago
GuruFocus.com
20 days ago
GlobeNewswire
25 days ago
GlobeNewswire
a month ago
MT Newswires
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
The information presented on this page, "BCAB BioAtla Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.